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Chlamydia muridarum: Two different isolates of mouse adapted Chlamydia trachomatis Weiss strain were 
used to intranasally infect BALB/c mice at various concentrations. Group A mice were intranasally infected 
with 1 x 10^2 or 1 X 10^5 IFU’s of C Small Weiss (MoPn in vivo passage). Group B mice were intranasally 
infected with 1 x 10^1 or 1 x 10^5 IFU of mouse pneumonitis Weiss (MoPn stock strain). 
Infection of Mice and Tissue Preparation: Mice were intranasally infected with either C Small Weiss or 
mouse pneumonitis. Mice were sacrificed 60 days p.i, brains were removed and  immersion fixed in 4% 
paraformaldehyde, embedded in paraffin, and coronally sectioned at 7-10 micron thickness. 
Mouse Brain Tissue: A total of 50 coronal brain sections were immunolabeled per mouse. Five sets of 10 
sections: two sets were labeled with C. trachomatis specific antibody (10C-CR2104M1, 10C2104M3) , two 
sets were labeled with beta-amyloid specific antibody (AB1-16 6E10, AB (H-43) SC9129) and one set did 
not receive primary antibody and was used as a negative control. In order provide representative samples 
from areas throughout the whole brain sections were selected every 70-100 microns from rostral (bregma + 
2.22mm) to caudal (bregma -5.88mm) (Figure 1). 
Antibodies: The primary antibodies specific for C. trachomatis used were: mouse monoclonal 10C-
CR2104M1 at a working concentration of 2 micrograms/mL(Fitzgerald, Acton, MA),  mouse monoclonal 
10C-CR2104M3 at a working concentration of 2 micrograms/mL((Fitzgerald, Acton, MA), and Anti-C 
muridarum (Sera mouse Anti-MoPn) at a working concentration of 1:500. The primary antibodies that were 
used to detect B-Amyloid are: rabbit polyclonal sc-9129 at a working concentration of 4 micrograms/mL 
(Santa Cruz Biotechnology) and mouse monoclonal 6E10 at a working concentration of  2 micrograms/mL 
(Covance). To visualize the respected antigen alkaline phosphatase conjugated goat anti-mouse and anti-
rabbit  secondary antibodies were utilized (Life Technologies, Carlsbad, CA) at a dilution of 1:400 (1.25 
micrograms/mL).  Antibodies were diluted to working concentration using phosphate buffer saline+2% fetal 
bovine serum.  
Immunohistochemistry: Mouse brain coronal sections were first rehydrated for 3 minutes  in xylene 3x, 
followed by 100% ethanol x2, 90% ethanol x1, 70% ethanol x1 (Electron Microscopy Sciences, Fort 
Washington, PA). Next, slides were washed in DI H2O for 2 x 3 minutes, then placed in Citra antigen 
retrieval buffer (BioGenex, San Roman, CA) and steamed at high pressure for 15 minutes at 120 degrees 
Celsius in a 2010 Retreaver (Pick Cell Laboratories, Amsterdam, Netherlands). Slides remained in antigen 
retrieval buffer overnight at room temperature. Slides were washed with phosphate buffered saline pH 7.4 
(PBS) 3 x 5 minutes. Next, Alkaline Phosphatase Horseradish Peroxidase  was applied to the slides for 5 
minutes to quench endogenous peroxidase activity, washed 3 x 5 minutes in PBS. Slides were incubated in 
mouse on mouse (MOM) blocking reagent  (Vector Labs) was used 1 x 15 minutes. Following MOM, slides 
were blocked 1 x 15 minutes in PBS+2%FBS (Mediatech, Herndon, VA). Primary antibodies 10C-
CR2104M1, 10C2104M3, Anti- C muridarum, AB1-16 6E10, AB (H-43) SC9129 were applied and slides 
placed in a humidified chamber at 37 degrees Celsius for 90 minutes. Next, slides were washed 3 x 5 
minutes in PBS and blocked 2 x 15 minutes in 2% PBS+2%FBS. Secondary antibodies were applied to 
each slide and slides were incubated for 60 minutes in a humidified chamber at 37 degrees Celsius. Next, 
slides were washed 3 x 5 minutes in DI water (DI H2O). Slides were developed for 15 minutes using 
alkaline phosphatase new magenta (BioFX, Owings Mills, MD). Next, slides were washed in DI H2O 3 x 5 
minutes and PBS 1 x 5 minutes. To stain the tissue Acidified Harris’s Hematoxylin (Mercury free) was 
applied for 1 minute. The slides were rinsed briefly with DI H2O then washed with PBS for 5 minutes to 
produce a color change. Finally slides were washed 3 x 5 minutes w/ DI H2O then wiped down and air 
dried. Once dry slides were glycerol mounted and coverslipped. 
Microscopic Analysis: Tissue was examined using 10x, 20x and 40x power objectives. Images were 
captured using NIS-Elements F 2.20 Imaging Systems software on a Nikon Eclipse 50i microscope using a 
Nikon Digital Sight DS-DM Camera.  
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1.Substantial chlamydia and amyloid labeling at the 2 month time point following 
intranasal infection with Chlamydia pneumoniae suggests that the chlamydia 
infection induces amyloid pathology. 
 
2.Amyloid deposition at the 2 month time point in mice intranasally infected with 
Chlamydia muridarum demonstrates that infection with this bacterium induces 
amyloid pathology. 
 
3.The substantial increase in amyloid deposition and chlamydia labeling 
observed following infection with the C Small Weiss (MoPn in vivo passage) 
strain differs from the slight increase in amyloid labeling detected following 
infection with the mouse pneumonitis strain (MoPn stock strain) suggests that the 
degree of pathology induced following infection varies based upon the isolate of 
chlamydia introduced. 
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Abstract 
Previous research indicates BALB/c mice inoculated with Chlamydia pneumoniae (Cpn) demonstrated AD-
like pathology which suggests that this mouse model is valid for studying the pathogenesis implicated in 
Alzheimer’s disease (AD). Studies have demonstrated that Chlamydia trachomatis (Ctr) can disseminate 
from its primary site of infection and plays a major role in the induction of reactive arthritis. The objectives 
of this lab are: (1)to identify and localize Chlamydia antigens in the brains of BALB/c mice infected with C. 
muridarum and (2) to determine if infection with C. muridarum induces AD-like pathology comparable to 
Cpn. Using mouse adapted respiratory isolates of C. muridarum, we investigated whether C. muridarum 
disseminated from the respiratory tract to the brain. Mice were intranasally infected with plaqued C small 
Weiss (CSW) or plaqued mouse pneumonitis Weiss (MoPn weiss). Brain tissue was isolated at 2 months 
post-infection. Serial sections from brains infected mice were analyzed for amyloid or Chlamydia antigens. 
Preliminary analysis of brain tissue demonstrated no detectable difference in C. muridarum antigen 
between mice receiving 1 x105 IFU and mice receiving 1 x101 IFU, whereas a small but detectable 
difference was identified in amyloid-specific labeling between these two experimental groups. In contrast, 
prominent Chlamydia-specific labeling was identified in the brains of Cpn-infected mice as well as 
substantial amyloid deposition at 2 months p.i.. These data suggest that, relative to Cpn AR-39 infection, 
C. muridarum infection is a weaker stimulus for inflammation, resulting in decreased amyloid deposition in 
the brains of BALB/c mice. 
     Alzheimer’s disease (AD) is progressive neurodegenerative disease that affects one in eight older 
Americans. It is the most common form of dementia accounting for sixty to eighty percent of all cases and 
is the fifth leading cause of death for individuals age 65 and older. [1]. Due to its high prevalence, 
continued research on AD will be important in not only determining causes and risk factors but also 
developing treatment and improving patient’s quality of life. 
     Alzheimer's disease is characterized by a progressive loss in cognitive function with the accumulation 
of the defining neuropathology amyloid (senile) plaques and neurofibrillary tangles in brain tissue. Decline 
in cognitive function is caused by neuronal cell death in areas of the brain associated with memory such 
as the medial temporal lobe and cortical structures. Neuronal cell death is induced by extracellular amyloid 
accumulation which disrupts normal synaptic communication within the brain. The formation of tangles 
within the neuron induces apoptosis by interfering with normal cellular function and transport of nutrients. 
Early AD pathology involves the medial temporal lobe which includes the hippocampus and the entorhinal 
cortex. [1,2]. Both of these regions are important for memory [3]. As the disease progresses, motor and 
sensory function become compromised and the disease is ultimately fatal [1]. 
     There are two different forms of AD, sporadic and familial. Familial AD (FAD) accounts for less than 5% 
of AD cases and is caused by genetic mutations. Patients with FAD develop AD pathology before the age 
of 65. Genetic mutations associated with FAD involve mutations of the amyloid precursor protein and 
presenilin 1 and 2 [4]. A mutation in any of these proteins will lead to an early accumulation of amyloid 
plaques within brain tissue. [2,5]. While there is a known cause for FAD, the cause of sporadic AD which 
accounts for more than 95% of AD cases has not been identified. Several risk factors have been 
recognized including mild cognitive impairment, cardiovascular disease, head trauma, and inflammation. 
[2,6]. In 1998 Balin and coworkers identified and infectious agent, Chlamydia pneumoniae (Cpn) in 17 of 
19 AD brains, suggesting the potential role of infection in the induction or progression of AD [7].  
     Two members of the genus Chlamydiae, C. trachomatis and C. pneumoniae, play a role in acute and 
chronic human illness [8] and have been shown to induce a chronic inflammatory response. Following the 
establishment of a urogenital infection by Chlamydia trachomatis, this organism has also been implicated 
in reactive arthritis, a chronic inflammatory joint condition [9, 10]. C. trachomatis can also ascend from its 
primary site of infection in the lower genital tract to the fallopian tubes and cause complications such as 
pelvic inflammatory disease which may result in infertility [11,12]. Chlamydia pneumoniae, a respiratory 
pathogen, has been shown to establish chronic infection and has been implicated in coronary artery 
disease [13], multiple sclerosis [14], and AD [7]. Mouse models have shown that this strain of chlamydia 
can disseminate after intranasal inoculation. The bacterium travels via peripheral blood monocytes and 
macrophages and has been found in areas not typically associated with C. pneumoniae- respiratory 
infection such as the spleen, aorta, and abdominal lymph nodes [7,15].     Thus, the ability of C. 
pneumoniae to disseminate and establish chronic infection may promote pathology in tissue other than 
respiratory epithelium. 
      To address the potential role of Chlamydia in the induction of sporadic AD, this laboratory has 
developed a mouse model in which AD-like pathology is induced following the introduction of C. 
pneumoniae.  This model involves intranasally infecting non-transgenic BALB/c mice with C. pneumoniae 
[16].  In contrast with transgenic mice, the use of BALB/c mice more accurately models the predominant 
form of AD (sporadic/late onset) because these mice do not harbor any (human) genes.  Pathology is 
induced following infection with C. pneumoniae [16].  This bacterium is commonly associated with 
respiratory infections worldwide in humans and was first associated with AD following identification and 
isolation from post-mortem brain tissue of individuals with AD in 1998 [17].  This laboratory has shown that 
following intranasal infection of mice, this organism establishes a chronic infection in the olfactory bulbs 
and induces substantial pathological deposition of Aβ in the brain [16].   
      The work presented here continues previous studies involving the BALB/c mouse model of AD-like 
pathology following C. pneumoniae infection.  The focus of this research is to investigate the presence of 
the respiratory adapted biovar of C. muridarum, in fixed and embedded mouse brain tissue previously 
infected with this organism.  Analysis was conducted using immunohistochemistry to label Chlamydia-
specific antigens and beta amyloid deposits followed by a semi-quantitative microscopic analysis of brain 
tissue.  The goal of this work was to investigate the relationship between the relative amount and location 
of Chlamydia antigens to that of AD-like pathology and to determine whether infection with C. muridarum 
induces AD-like pathology comparable to C. pneumoniae. 
 
 
Chlamydia (Cpn) Antigen and Amyloid Deposition (Dep) 
Location of C. pneumoniae immunoreactivity and amyloid deposits over 1, 2, 3, and 4 months 
post infection within brains of C. pneumoniae-infected mice.  The location of immunoreactive 
label to amyloid deposits or Chlamydial antigen is designated in millimeters (Section location in 
mm) rostral or caudal to the mouse bregma. Gray, hatched, and aqua shaded areas highlight 
majority of C. pneumoniae antigen and the relationship to the majority of amyloid deposition 1 
month later.  
 Rostral  Bregma     Caudal  
Section 
Location 
(mm) 2.22 1.70 0.38 -1.28 -2.75 -3.80 -4.92 -5.46 -5.88 Total 
1 Mon 
Cpn  22 10 22 18 23 42 9 6 2 154 
 
 Amyloid  0 1 0 3 3 0 1 0 0 8 
2 Mon 
Cpn  18 15 19 5 26 21 20 10 0 134 
 
Amyloid  8 30 0 0 26 19 26 0 0 109 
3 Mon 
Cpn  11 11 13 22 5 9 9 4 7 91 
 
Amyloid  0 2 12 1 0 0 1 1 0 17 
4 Mon 
Cpn  0 11 13 15 13 10 10 1 3 76 
 
Amyloid  0 0 0 1 3 0 5 0 0 9 
Cpn 
Totals 51 47 67 60 67 82 48 21 12 455 
Amyloid 
Totals 8 33 12 5 32 19 33 1 0 143 
A.                                                                Bregma 
 
B. 
 
Anatomic Location of Representative Coronal Sections  
In panel A, red lines indicate the location of selected Coronal sections from the Mouse Brain Library, providing 
an analysis of the whole brain. Sections rostral (red circles) to bregma (yellow circle) and caudal to bregma 
(blue circles) are displayed. Particular regions of interest, related to Alzheimer’s disease, are identified in panel 
B. 
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Chlamydia (Cmu) Antigen  and Amyloid Deposition 
Location of C. muridarum immunoreactivity and amyloid deposition at day 60 post infection within the 
brains of mouse pneumonitis in vivo passage and mouse pneumonitis stock strain infected mice. The 
location of the immunoreactive label to amyloid or chlamydial antigen is designated in millimeters 
(section location in mm) rostral or caudal to the mouse bregma. The dash mark (-) indicates that no data 
was collected.  
 
 
 
Section 
Location 
(mm) 
Bregma 
 
0.00 
 
 
-1.28 
 
 
-2.75 
 
 
-3.80 
Caudal 
 
-4.82 
 
 
Total 
 
 
Total/Mouse 
MoPn in vivo Day 60 p.i 
Titer Negative 
Infected Mice 
(n=2) 
Cmu Ag 0 4 11 7 - 22 11 
Amyloid 0 3 2 1 - 6 3 
Titer Positive 
Infected Mice 
(n=2) 
Cmu Ag 0 5 0 23 20 48 24 
Amyloid 0 5 - 7 44 56 28 
MoPn stock strain Day 60 p.i 
Titer Negative 
Infected Mice 
(n=1) 
Cmu Ag - 0 0 7 - 7 7 
Amyloid - 0 0 2 - 2 2 
Titer Positive 
Infected Mice 
(n=3) 
Cmu Ag 4 8 0 1 4 17 5.67 
Amyloid 1 12 2 3 7 25 8.33 
